Minerva Neurosciences (NERV) Competitors $2.49 -0.04 (-1.58%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.50 +0.01 (+0.60%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity Minerva Neurosciences (NASDAQ:NERV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Is NERV or ATNFW more profitable? 180 Life Sciences' return on equity of 0.00% beat Minerva Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A -41.35% 31.37% 180 Life Sciences N/A N/A N/A Does the media favor NERV or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Minerva Neurosciences Neutral 180 Life Sciences Neutral Do analysts rate NERV or ATNFW? Minerva Neurosciences currently has a consensus target price of $5.00, suggesting a potential upside of 100.80%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, NERV or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A$1.44M$1.481.68180 Life SciencesN/AN/AN/AN/AN/A Do institutionals and insiders believe in NERV or ATNFW? 34.6% of Minerva Neurosciences shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryMinerva Neurosciences beats 180 Life Sciences on 5 of the 7 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.62B$6.13B$10.55BDividend YieldN/A57.79%5.72%4.83%P/E Ratio1.6823.3151.2627.06Price / SalesN/A778.09602.44132.30Price / Cash11.9127.2425.8230.35Price / Book-0.685.3212.246.58Net Income$1.44M$33.06M$3.33B$276.84M7 Day Performance-1.58%-0.91%0.62%-0.72%1 Month Performance22.66%7.35%6.83%2.16%1 Year Performance-0.80%-5.13%59.07%34.63% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences2.8078 of 5 stars$2.49-1.6%$5.00+100.8%-0.8%$0.00N/A1.689Gap DownATNFW180 Life SciencesN/A$0.06-7.7%N/A+295.3%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.23+26.3%N/AN/A$0.00$110.87K0.0040Positive NewsALVOWAlvotechN/A$1.31-11.8%N/AN/A$0.00$560.10M0.004Gap UpARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+24.8%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10+3.1%N/A+387.3%$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01+6.3%N/A-98.6%$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.04-7.2%N/A-82.1%$0.00N/A0.008Negative NewsGap UpCELUWCelularityN/A$0.03-24.6%N/A+133.8%$0.00$44.59M0.00220Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Ainos Alternatives Alvotech Alternatives Aravive Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCould this strange machine change society forever?A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
